Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
Clinical trial NCT05222555 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05222555
- Sponsor
- Incyte Corporation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-19
- Primary completion
- 2024-07-17
- Enrollment
- 53
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.